Tue, 21/02/2017 - 07:30
Cleveland, UK, 21st February 2017 / Sciad Newswire / Cambridge Research Biochemicals® (CRB), a longstanding
Tue, 14/02/2017 - 07:30
London, UK, 14th February 2017 / Sciad Newswire / Biosys UK Limited (“Biosys” or the “Company
Fri, 10/02/2017 - 09:30
Ongar, UK, 10th February 2017 / Sciad Newswire / Selcia, with colleagues from Cypralis and Gilead Sciences Inc., have publish
Tue, 31/01/2017 - 09:53
Dallas, USA, 29th January 2017 / Sciad Newswire / CancerGene Connect, a wholly owned Subsidiary of OMMDOM, Inc.,
Mon, 23/01/2017 - 07:30
Cambridge, UK, 23rd January 2017 / Sciad Newswire / Cypralis, a life sciences company focused on the discovery of therapeut
Wed, 04/01/2017 - 07:30
Edinburgh, UK, 4th January 2017 / Sciad Newswire / Synpromics Ltd, the leading synthetic promoter and gene control compan
Wed, 04/01/2017 - 07:00
Prokarium and Probiomed today announced the start of their collaboration to scale-up the manufacture of orally administered vaccines in a formulation that would enable stability at 40°C for several weeks. The first vaccine to be manufactured will be developed to prevent so-called ‘Montezuma’s revenge’ or diarrhoea, which affects the local population as well travellers in Mexico and many countries.
Sir Simon Campbell and Tom Mander
Thu, 17/11/2016 - 15:00
Saffron Walden​, UK, 17th November 2016 / Sciad Newswire / Saffron Walden, UK, 17th November 2016 / Sir Simon Campbell, CBE FRS FMedSci, was welcomed b
Thu, 17/11/2016 - 14:30
London, UK, 17th November 2016 / Sciad Newswire / The pharmaceutical industry is a sector of strategic importance, standing on the threshold of innovation, sa
Mon, 31/10/2016 - 09:00
ReViral, an antiviral drug discovery and development company developing innovative therapies against Respiratory Syncytial Virus (RSV), announced today the initiation of a Phase 1 clinical trial for RV521, its novel orally-active small molecule inhibitor of RSV fusion.